000 01291 a2200373 4500
005 20250517024022.0
264 0 _c20161213
008 201612s 0 0 eng d
022 _a0048-7449
024 7 _a10.4081/reumatismo.2014.799
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRossini, M
245 0 0 _aWhy golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
_h[electronic resource]
260 _bReumatismo
_cMar 2015
300 _a285-303 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntirheumatic Agents
_xtherapeutic use
650 0 4 _aArthritis, Psoriatic
_xdrug therapy
650 0 4 _aArthritis, Rheumatoid
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aRandomized Controlled Trials as Topic
650 0 4 _aSpondylitis, Ankylosing
_xdrug therapy
650 0 4 _aTreatment Outcome
700 1 _aViapiana, O
700 1 _aOrsolini, G
700 1 _aFracassi, E
700 1 _aIdolazzi, L
700 1 _aGatti, D
700 1 _aAdami, S
700 1 _aGovoni, M
773 0 _tReumatismo
_gvol. 66
_gno. 4
_gp. 285-303
856 4 0 _uhttps://doi.org/10.4081/reumatismo.2014.799
_zAvailable from publisher's website
999 _c24761742
_d24761742